The change of prefrontal QEEG theta cordance as a predictor of response to bupropion treatment in patients who had failed to respond to previous antidepressant treatments

European Neuropsychopharmacology

Volumn 20, Issue 7, 2010, Pages 459-466

  Bares, Martin ^a,b   Brunovsky, Martin ^a,b,c   Novak, Tomas ^a,b   Kopecek, Miloslav ^a,b   Stopkova, Pavla ^a,b   Sos, Peter ^a,b   Krajca, Vladimir ^c,d   Höschl, Cyril ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^d CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

Author keywords

Bupropion; Depression; Prediction; QEEG cordance; Treatment outcome

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; CLOMIPRAMINE; DIBENZEPIN; ESCITALOPRAM; HYDROXYZINE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; RISPERIDONE; TRAZODONE; VENLAFAXINE; ZOLPIDEM;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ELECTRODE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THETA RHYTHM; TREATMENT DURATION;

ADULT; ANTIDEPRESSIVE AGENTS; BUPROPION; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREFRONTAL CORTEX; STATISTICS, NONPARAMETRIC; THETA RHYTHM;

EID: 77953360332     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.03.007     Document Type: Article

References (49)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Press, Washington DC. 4th ed.
2. Asada H., Fukuda Y., Tsunoda S., Yamaguchi M., Tonoike M. Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci. Lett. 1999, 274:29-32.
3. Bares M., Brunovsky M., Kopecek M., Stopkova P., Novak T., Kozeny J., Höschl C. Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J. Psychiatr. Res. 2007, 41:319-325.
4. Bares M., Brunovsky M., Kopecek M., Novak T., Stopkova P., Kozeny J., Sos P., Krajca V., Höschl C. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur. Psychiatry 2008, 23:350-355.
5. Bazire S. Psychotropic Drug Directory 2003/04. The Professionals' Pocket Handbook & Aide Memoire 2003, Five Pin Publishing Limited, Salisbury.
6. Beck A.T., Rial W.Y., Rickels K. Short form of depression inventory: cross-validation. Psychol. Rep. 1974, 34:1184-1186.
7. Cohen J. Statistical Power Analyses for the Behavioral Sciences 1988, Lawrence Earlbaum Association, Hillsdale. 2nd ed.
8. Cook I.A. Biomarkers in psychiatry: potentials, pitfalls, and pragmatics. Primary Psychiatry 2008, 15:54-59.
9. Cook I.A., Leuchter A.F. Prefrontal changes and treatment response prediction in depression. Semin. Clin. Neuropsychiatry 2001, 6:113-120.
10. Cook I.A., O'Hara R., Uijtdehaage S.H., Mandelkern M., Leuchter A.F. Assessing the accuracy of topographic EEG mapping for determining local brain function. Electroencephalogr. Clin. Neurophysiol. 1998, 107:408-414.
11. Cook I.A., Leuchter A.F., Morgan M., Witte E., Stubbeman W.F., Abrams M., Rosenberg S., Uijtdehaage S.H. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology 2002, 27:120-131.
12. Cook I.A., Leuchter A.F., Morgan M.L., Stubbeman W., Siegman B., Abrams M. Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J. Psychiatr. Res. 2005, 39:461-466.
13. Drevets W.C. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu. Rev. Med. 1998, 49:341-361.
14. Drevets W.C., Price J.L., Furey M.L. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 2008, 213:93-118.
15. Guy W. ECDEU assessment manual for psychopharmacology- revised. US Dept. Health, Education and Welfare Publication (ADM) 76-338 1976, 218-222. National Institute of Mental Health, Rockville, MD.
16. Fredman S.J., Fava M., Kienke A.S., White C.N., Nierenberg A.A., Rosenbaum J.F. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J. Clin. Psychiatry 2000, 61:403-408.
17. Hjorth B. An on-line transformation of EEG scalp potentials into orthogonal source derivations. Electroencephalogr. Clin. Neurophysiol. 1975, 39:526-530.
18. Hunter A.M., Cook I.A., Leuchter A.F. The promise of the quantitative electroencephalogram as a predictor of antidepressant treatment outcomes in major depressive disorder. Psychiatr. Clin North. Am. 2007, 30:105-124.
19. Keller M.B. Issues in treatment-resistant depression. J. Clin. Psychiatry 2005, 66(Suppl 8):5-12.
20. Kennedy S.H., Fulton K.A., Bagby R.M., Greene A.L., Cohen N.L., Rafi-Tar S. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can. J. Psychiatry 2006, 51:234-242.
21. Kornstein S.G., Sloan D.M.E. Depression and gender. Textbook of Mood Disorders 2006, 687-698. American Psychiatric Publishing, Inc., Arlington. D.J. Stein, D.J. Kupfer, A.F. Schatzberg (Eds.).
22. Leuchter A.F., Cook I.A., Lufkin R.B., Dunkin J., Newton T.F., Cummings J.L., Mackey J.K., Walter D.O. Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage 1994, 1:208-219.
23. Leuchter A.F., Cook I.A., Mena I., Dunkin J.J., Cummings J.L., Newton T.F., Migneco O., Lufkin R.B., Walter D.O., Lachenbruch P.A. Assessment of cerebral perfusion using quantitative EEG cordance. Psychiatry Res. 1994, 55:141-152.
24. Leuchter A.F., Cook I.A., Witte E.A., Morgan M., Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am. J. Psychiatry 2002, 159:122-129.
25. Leuchter A.F., Uijtdehaage S.H., Cook I.A., O'Hara R., Mandelkern M. Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999, 90:125-140.
26. Lozano A.M., Mayberg H.S., Giacobbe P., Hamani C., Craddock R.C., Kennedy S.H. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol. Psychiatry 2008, 64:461-467.
27. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., Silva J.A., McGinnis S., Glass T.G., Martin C.C., Fox P.T. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
28. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 2000, 48:830-843.
29. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
30. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
31. Morgan M.L., Witte E.A., Cook I.A., Leuchter A.F., Abrams M., Siegman B. Influence of age, gender, health status, and depression on quantitative EEG. Neuropsychobiology 2005, 52:71-76.
32. Mulert C., Juckel G., Brunnmeier M., Karch S., Leicht G., Mergl R., Möller H.J., Hegerl U., Pogarell O. Rostral anterior cingulate cortex activity in the theta band predicts response to antidepressive medication. Clin. EEG Neurosci. 2007, 38:78-81.
33. Nierenberg A.A., Farabaugh A.H., Alpert J.E., Gordon J., Worthington J.J., Rosenbaum J.F., Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 2000, 157:1423-1428.
34. Nuwer M.R., Lehmann D., da Silva F.L., Matsuoka S., Sutherling W., Vibert J.F. IFCN guidelines for topographic and frequency analysis of EEGs and EPs. Electroencephalogr. Clin. Neurophysiol. 1999, 52:15-20. Suppl.
35. Papakostas G.I., Kornstein S.G., Clayton A.H., Soares C.N., Hallett L.A., Krishen A., Tucker V.L. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Int. Clin. Psychopharmacol. 2007, 22:226-229.
36. Papakostas G.I., Petersen T., Sklarsky K.G., Nierenberg A.A., Alpert J.E., Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007, 149:195-200.
37. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol. Psychiatry 2008, 63:699-704.
38. Pizzagalli D., Pascual-Marqui R.D., Nitschke J.B., Oakes T.R., Larson C.L., Abercrombie H.C., Schaefer S.M., Koger J.V., Benca R.M., Davidson R.J. Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am. J. Psychiatry 2001, 158:405-415.
39. Pizzagalli D.A., Oakes T.R., Davidson R.J. Coupling of theta activity and glucose metabolism in the human rostral anterior cingulate cortex: an EEG/PET study of normal and depressed subjects. Psychophysiology 2003, 40:939-949.
40. Quitkin F.M., Petkova E., McGrath P.J., Tailor B., Beasley C., Stewart J., Amsterdam J., Fava M., Rosenbaum J., Reimherr F., Fawcett J., Chen Y., Klein D. When should a trial of fluoxetine for major depression be declared failed?. Am. J. Psychiatry 2003, 160:734-740.
41. Rush A.J., Kraemer H.C., Sackeim H.A., Fava M., Trivedi M.H., Frank E., Ninan P.T., Thase M.E., Gelenberg A.J., Kupfer D.J., Regier D.A., Rosenbaum J.F., Ray O., Schatzberg A.F., Task Force A.C.N.P. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006, 31:1841-1853.
42. Rush A.J., Trivedi M.H., Wisniewski S.R., Stewart J.W., Nierenberg A.A., Thase M.E., Ritz L., Biggs M.M., Warden D., Luther J.F., Shores-Wilson K., Niederehe G., Fava M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006, 354:1231-1242. STAR*D Study Team.
43. Sackeim H.A. The definition and meaning of treatment-resistant depression. J. Clin. Psychiatry 2001, 62(Suppl 16):10-17.
44. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl 20):22-33.
45. Souery D., Oswald P., Massat I., Bailer U., Bollen J., Demyttenaere K., Kasper S., Lecrubier Y., Montgomery S., Serretti A., Zohar J., Mendlewicz J. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 2007, 68:1062-1070. Group for the Study of Resistant Depression.
46. Szegedi A., Jansen W.T., van Willigenburg A.P., van der Meulen E., Stassen H.H., Thase M.E. Early improvement in the first 2weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J. Clin. Psychiatry 2009, 70:344-353.
47. Thase M.E., Rush A.J. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J. Clin. Psychiatry 1997, 58(Suppl 13):23-29.
48. Trivedi M.H., Morris D.W., Grannemann B.D., Mahadi S. Symptom clusters as predictors of late response to antidepressant treatment. J. Clin. Psychiatry 2005, 66:1064-1070.
49. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40. STAR*D Study Team.